Work

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections

Year: 2019

Type: article

Abstract: Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1 and -2). Seven hundred ninety baseline isolates, including Staphylococcus aureus , β-hemolytic streptococci, and Streptococcus anginosus group, underwent antibacterial susceptibility testing.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.02239-18

Authors: Stephanie Noviello, Sophie Magnet, Stephen Hawser, David B. Huang

Institutions: Motif BioSciences (United States), Rutgers New Jersey Medical School

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2909927190